|
|
||||||||
1 Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226; and 2 Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas 75390
| |
ABSTRACT |
|---|
|
|
|---|
Mediator contributions to hypoxic
dilation of rat gracilis muscle resistance arteries were determined by
measuring dilation, vascular smooth muscle hyperpolarization, and
metabolite production after incremental hypoxia. Nitric oxide (NO)
synthase inhibition abolished responses to mild hypoxia, whereas COX
inhibition impaired responses to more severe hypoxia by 77%. Blocking
20-hydroxyeicosatetraenoic acid (20-HETE) impaired responses to
moderate hypoxia. With only NO systems intact, responses were
maintained with mild hypoxia (88% normal) mediated via KCa
channels. When only COX pathways were intact, responses to
moderate-severe hypoxia were largely retained (79% of normal) mediated
via KATP channels. Vessel responses to moderate hypoxia
were retained with only 20-HETE systems intact mediated via
KCa channels. NO production increased 5.6-fold with mild
hypoxia; greater hypoxia was without further effect. With increased
hypoxia, 20-HETE levels fell to 40% of control values. 6-keto-PGF1
levels were not altered with mild hypoxia,
but increased 4.6-fold with severe hypoxia. These results suggest vascular reactivity to progressive hypoxia represents an integration of
NO production (mild hypoxia), PGI2 production (severe
hypoxia), and reduced 20-HETE levels (moderate hypoxia).
nitric oxide; prostacyclin; skeletal muscle microcirculation; oxygen-induced vascular reactivity; cytochrome P-450 4a enzymes; microvessels; 20-hydroxyeicosatetraenoic acid
| |
INTRODUCTION |
|---|
|
|
|---|
THROUGHOUT THE BODY, microvessels use a complex array of integrative mechanisms to regulate their tone in response to a wide variety of vasoactive stimuli and physiological processes (10, 13). Of these numerous contributing factors, investigation into the role of oxygen in mediating vascular tone has produced a considerable body of literature, albeit one with little consensus on mechanisms underlying the observations. As such, determining the manner in which these processes integrate to produce net responses of microvessels to altered oxygen tension remains an elusive target.
With specific regard to skeletal muscle microvessel reactivity to altered PO2, results from previous studies have suggested that either endothelium-derived nitric oxide (NO; 14, 22), endothelium-derived prostacyclin (PGI2; 5-8, 17-20), or smooth muscle-derived 20-hydroxyeicosatetraenoic acid (20-HETE; 6, 7, 11, 16) may be the predominant mediator of this process, although a recent study (6) also suggested that endothelium-derived epoxyeicosatrienoic acids (EETs) may also play a contributing role. Despite the fact that these studies encompass skeletal muscle microvessels ranging from resistance arteries to distal arterioles and that vessels from different skeletal muscles studied under different conditions have been employed for these studies, it can be difficult to reconcile the wide divergence in proposed mediators of vessel dilation to reduced oxygen tension. It is clearly necessary to systematically dissect, within specific vascular segments, the pathways contributing to O2-induced alterations in microvessel tone. The present study was performed to determine the interaction and relative contribution of the predominant mediators of hypoxic dilation to the relaxation and vascular smooth muscle (VSM) membrane hyperpolarization of resistance arteries serving rat gracilis muscle during exposure of these vessels to incremental levels of hypoxia similar to those that may be encountered under a variety of in vivo conditions. We hypothesize that responses of skeletal muscle resistance arteries to incremental, graded reductions in PO2 do not reflect a single mechanism, but rather are the integrated effect of multiple mechanisms acting through the range of hypoxia to contribute to the dilation and VSM hyperpolarization that occur in these vessels' response to reduced oxygen tension. It is important to emphasize that the purpose of the present study was not to determine which signaling pathways contribute to the dilation of skeletal muscle microvessels in response to reduced PO2, as this has been investigated in considerable detail in the previous studies cited above. Determining the interplay of significant mediators of hypoxia-induced alterations in vascular tone in these vessels represents an important avenue of investigation, as they lie immediately proximal to the microcirculation per se and play a critical role in regulating the flow of blood through distal arteriolar networks (4).
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Animals. All experiments employed 9- to 14-wk-old male Sprague-Dawley rats (weight = 319 ± 13 g, mean arterial pressure = 109 ± 6.4 mmHg) maintained on standard rat chow and tap water ad libitum. Rats were housed in an animal care facility at the Medical College of Wisconsin that is accredited by the American Association for the Accreditation of Laboratory Animal Care and all protocols received prior approval from the Institutional Animal Care and Use Committee. Rats were anesthetized with an injection of pentobarbital sodium (60 mg/kg ip), and a carotid artery was cannulated for determination of arterial pressure immediately before isolation of vessels for study.
Preparation of isolated vessels. The small muscular branch of the femoral artery supplying the gracilis muscle was removed from the anesthetized rat, taking care to minimize vessel stretching and to handle arteries by their surrounding connective tissue only. Arteries were placed in a heated chamber (37°C) that allowed the lumen and exterior of the vessel to be perfused and superfused, respectively, with physiological salt solution (PSS) from separate reservoirs. The PSS used in these experiments was equilibrated with a 21% O2, 5% CO2, and 74% N2 gas mixture and had the following composition (mM): 119 NaCl, 4.7 KCl, 1.17 MgSO4, 1.6 CaCl2, 1.18 NaH2PO4, 24 NaHCO3, 0.026 EDTA, and 5.5 glucose. Vessels were cannulated at both ends with glass micropipettes and were secured to the inflow and outflow pipettes using 10-0 nylon suture. Any side branches were ligated with a single strand teased from 6-0 silk suture. The inflow pipette was connected to a reservoir perfusion system that allowed the intraluminal pressure and luminal gas concentrations to be controlled. Vessel diameter was measured using television microscopy and an on-screen video micrometer (15).
Arteries were extended to their approximate in situ length and were equilibrated at 80% of the animal's mean arterial pressure (88 ± 4.9 mmHg) to approximate in vivo perfusion pressure (15). Under these conditions, vessels experienced a wall shear stress ranging from 1.5 to 2.1 dynes/cm2. Vessels that did not demonstrate both a functional endothelium and active tone at rest (assessed by a brisk dilation in response to 10
6
M acetylcholine) were discarded. Active tone at the equilibration pressure was calculated as (
D/Dmax) · 100, where
D is the diameter increase from rest in response to
Ca2+-free PSS, and Dmax is the maximum diameter
measured at the equilibration pressure in Ca2+-free PSS.
Active tone for vessels in the present study averaged 35.5 ± 2.2%.
Measurement of VSM membrane potential.
VSM transmembrane potential was measured with a high-impedance
amplifier and glass microelectrodes (40-80 M
impedance) filled with 3 M KCl. Criteria for successful impalement included an abrupt drop to a steady level of transmembrane potential for a minimum of
5 s and a rapid return to baseline after removal of the electrode from the cell. Five measurements were made under each condition (i.e.,
in response to each challenge), and the results were averaged to obtain
the final value of transmembrane potential for that vessel under each
experimental condition (8, 17).
Assessment of vessel dilation and VSM hyperpolarization to hypoxia. Arterial dilation and VSM hyperpolarization in response to incremental hypoxia were determined at the equilibration pressure for each vessel. For each artery, the O2 content of the superfusate/perfusate equilibration gas was reduced from 21% O2 (145-150 mmHg at the vessel) to either 15% O2 (115-120 mmHg at the vessel), 10% O2 (80-85 mmHg at the vessel), 5% O2 (60-65 mmHg at the vessel), or 0% O2 (35-40 mmHg at the vessel). All gas equilibration mixtures contained 5% CO2 and balance N2. For the determination of oxygen tension experienced by the isolated vessel, oxygen electrodes were placed within the vessel chamber and at the opening of the perfusate cannula leading into the vessel tension (5). Vessel diameter and VSM transmembrane potential measurements were taken after 30 min at each O2 level, and the imposed levels of hypoxia were randomized for all experiments. All measurements were taken under no-flow conditions, with the intraluminal pressure within the vessel at 80% of the mean arterial pressure for the individual animal (see above).
Removal of the vascular endothelium.
The endothelium of isolated vessels was removed via air bolus perfusion
(7). Endothelium denudation procedures were deemed successful when dilation in response to 10
6 M
acetylcholine was eliminated, whereas responses to 10
6 M
sodium nitroprusside were unaltered.
Inhibition of cytochrome P-450 systems.
To assess the role of arachidonic acid epoxidation in contributing to
hypoxic dilation of arteries, cytochrome P-450 (CP450) epoxygenases were inhibited with the suicide substrate
N-methylsulfonyl-6-(2-proparglyoxyphenyl)hexanoic acid
(MS-PPOH; 2×10
5 M; 6, 12). Direct measurements of
biochemical metabolites in rat renal microsomes indicated that MS-PPOH
is a selective inhibitor of arachidonic acid epoxidation, with minimal
effects on the
-hydroxylation reaction of arachidonic acid
(24). To evaluate the role of 20-HETE in regulating
arterial dilation to reduced PO2, these
responses were determined after addition of the synthetic compound
20-hydroxyeicosa-6(Z),15(Z)-dienoic acid [6(Z),15(Z)-20-HEDE;
10
6 M; 1, 7], a potent competitive antagonist of the
actions of 20-HETE, to the tissue bath.
Inhibition of potassium channels.
To determine the contribution of adenosine triphosphate-sensitive
potassium channels (KATP) and large conductance
Ca2+-activated potassium channels (KCa) to the
response of gracilis arteries to incremental hypoxia, these channels
were inhibited with glibenclamide (10
6 M; 7, 17) or
iberiotoxin (10
7 M; 3, 7, 9), respectively, in the vessel
chamber. Previous studies in our laboratory indicated that these
concentrations of glibenclamide and iberiotoxin effectively block
responses of resistance arteries to the prostacyclin analog iloprost
and 20-HETE, respectively (5, 7).
Inhibition of prostanoid and NO production.
To assess the role of prostanoid or NO release from the microvessel
endothelium in regulating the response of isolated arteries to reduced
PO2, the cyclooxygenase inhibitor indomethacin
(10
6 M; 7, 17) or the NO synthase inhibitor
NG-nitro-L-arginine methyl ester
(L-NAME; 10
4 M; 7, 21) was added to the
vessel bath to inhibit prostanoid or NO production, respectively.
Determination of NO production.
In a separate series of experiments, the generation of NO from gracilis
muscle resistance arteries was determined using an amperometric NO
sensor (ISO-NOP200 Mark II; World Precision Instruments). The sensor
was calibrated as described by the manufacturer by generating known
concentrations of NO in solution through the use of a 10
6
M solution of the NO donor S-nitroso-N-acetylpenicillamine
(SNAP). The calibration curve describing the sensitivity of the sensor to NO was determined using four dilutions of the SNAP solution and the
measured amperage from the NO sensor. With this use of basic
regression, this allowed for the determination of a linear relationship
between NO concentration within the diluted SNAP solutions and the
current measured by the sensor (r2 = 0.983).
Determination of prostacyclin production.
The production of PGI2 by gracilis muscle resistance
arteries in response to incremental hypoxia was assessed as described previously (15), with minor modification. Briefly, vessels
were removed from anesthetized rats and were pooled in the manner
described above. Vessels were incubated in glass vials in 1 ml of PSS
for 30 min under control conditions (21% O2), after which
the equilibration gas was switched to one of the other four mixtures
(randomized) or remained at 21% O2 for an additional 30 min. After the second 30-min period, the PSS was removed from the
incubation chamber, frozen in liquid N2, and stored at
80°C. Immediately, 1 ml of fresh PSS (equilibrated with 21%
O2) was added to the pooled vessels in the glass vial and
the procedure was repeated for the subsequent oxygen level.
PGI2 release by vessels under the different oxygen levels
was assessed in the Department of Physiology Biochemical Core Facility
at the Medical College of Wisconsin by measuring the level of
6-keto-prostaglandin F1
(6-keto-PGF1
), the stable metabolite of PGI2, in the incubation medium.
Measurements were made using a commercially available EIA kit purchased
from Cayman Chemical (Ann Arbor, MI). The numbers and grouping of
microvessels and rats for these experiments were identical to those
outlined for the Determination of NO production.
Determination of 20-HETE production. In the final series of experiments, 20-HETE production from gracilis arteries was determined using a fluorescence HPLC assay (18). Briefly, vessels were removed, pooled, and exposed to the different O2 levels as described above. After exposure to either 21% O2 or to one level of hypoxia, vessels were snap-frozen in liquid N2. Subsequently, the pooled arteries were homogenized, acidic lipids were extracted with ethyl acetate, and the samples were dried under nitrogen. The fatty acids were fluorescently labeled and separated using reverse-phase HPLC, as fully described previously (18). For each measurement of 20-HETE production, n = 4 gracilis arteries pooled from two rats under each of the five oxygen levels. Final values represent the data collected from four groups of rats (total = 40 rats).
Data and statistical analyses. All data are presented as means ± SE. For the present study, the mechanical and electrical responses of vessels in response to incremental hypoxia under control conditions (i.e., endothelium-intact vessels with no pharmacological intervention) are assumed to represent normal responses to reduced PO2 within those vessels. For the subsequent data presentation, vessel mechanical and electrical responses to each level of reduced PO2 under an experimental intervention (e.g., treatment with L-NAME) have been normalized to responses determined in untreated vessels within that subgroup. As a result, vascular responses to each reduction in PO2 in the experimental groups represent a percentage of the original control response to that level of hypoxia. For example, if dilation of a vessel under control conditions in response to a given level of hypoxia is 10 µm and treatment of the vessel with a pharmacological agent reduces this response to 4 µm, 40% of the normal reactivity of the vessel to hypoxia is retained after treatment with the drug. Statistically significant differences in resting diameter and VSM transmembrane potential of the vessel were determined using a one-way ANOVA, whereas responses to reduced PO2 and metabolite production with incremental hypoxia were determined using ANOVA or repeated-measures ANOVA, as appropriate. All analyses employed Tukey's post hoc test. For all analyses, P < 0.05 was taken to be statistically significant.
| |
RESULTS |
|---|
|
|
|---|
Data describing the diameter and VSM transmembrane potential of
isolated arteries under 21% O2 for the conditions of the
present study are presented in Table 1.
Treatment of arteries with glibenclamide or iberiotoxin caused a
significant constriction of the vessels and a significant
depolarization of the VSM membrane compared with values under control
conditions. Combined application of L-NAME and indomethacin
also caused a vasoconstriction and VSM depolarization from control
values.
|
Preliminary experiments performed in our laboratory indicated
that application of the prostacyclin analog iloprost (10
9
g/ml) and the NO donor
6-(2-hydroxy-1-methyl-2-nitrosohydrazino)-N-methyl-1-hexanamine (10
6 M) caused a significant hyperpolarization of the VSM
cell membrane of isolated gracilis arteries from
41.2 ± 0.5 mV
to
57.4 ± 1.8 mV and
59.3 ± 1.8 mV, respectively.
Mechanical and electrical responses of microvessels during
incremental hypoxia.
Figure 1 presents data describing
the dilation of isolated gracilis arteries (Fig. 1A) and the
hyperpolarization of the VSM membrane of these vessels (Fig.
1B) after incremental reductions in
PO2 under control conditions (i.e., intact
vessels with no pharmacological agent present). The progressive
reductions in oxygen tension caused significant increases in the
diameter and significant hyperpolarizations of the VSM membrane of
isolated gracilis arteries. Figure 1C presents the changes
in VSM transmembrane potential vs. arterial diameter in response to
incremental hypoxia. These data suggest that hypoxia-induced changes in
gracilis artery diameter are primarily a function of alterations in VSM
transmembrane potential.
|
|
|
|
|
Metabolite production from arteries in response to incremental
hypoxia.
Under control conditions (21% O2), pooled gracilis
arteries had an NO production of 4.5 ± 1.0 nmol/mg wet vessel
weight, a 6-keto-PGF1
production of 13.6 ± 1.9 pg/mg wet vessel weight, and a 20-HETE content of 2.0 ± 0.2 ng/mg
wet vessel weight. Representative chromatograms from the HPLC
determination of vascular 20-HETE content under conditions of 0%
O2 (Fig. 6A) and 21% O2 (Fig.
6B) are presented in Fig. 6.
Figure 7 presents data
describing changes in the production of NO, 6-keto-PGF1
,
and 20-HETE in isolated pooled arteries after graded reductions in
PO2. With mild hypoxia (15% O2),
NO release from vessels increased significantly from levels measured
under control conditions (Fig. 7A), but NO production exhibited no further increase with more severe hypoxia.
PGI2 release from vessels, estimated from its stable
breakdown product, 6-keto-PGF1
, was elevated only with
moderate to severe reductions in PO2 (Fig. 7B). 20-HETE production by vessels fell parallel to
PO2 (Fig. 7C), although the majority
of this effect occurred between 15% O2 and 5%
O2.
|
|
Interaction of vasoactive metabolites and potassium channels in
arteries with incremental hypoxia.
Data describing the interaction of KATP channels (Fig.
8A) and KCa channels (Fig. 8B) with
the predominant mediators of hypoxic dilation in isolated arteries are
presented in Fig. 8. Similar to data
presented in Fig. 5, inhibition of KATP channels with glibenclamide had no effect on arterial dilation in response to mild
hypoxia, but severely impaired this response with increasing hypoxia.
Combined application of glibenclamide with the NO synthase inhibitor
L-NAME eliminated vessel dilation in response to mild hypoxia, but had minimal further impact on the dilation of the vessels
with increased severity of hypoxia. Treatment of arteries with
glibenclamide and either indomethacin (to inhibit COXs) or 6(Z),15(Z),20-HEDE (to block the effects of 20-HETE) had minimal effect
on the dilation of vessels in response to incremental hypoxia compared
with arteries treated with glibenclamide alone. Also consistent with
data presented in Fig. 5, treatment of vessels with iberiotoxin (to
block KCa channels) abolished vessel dilation in response
to mild hypoxia and significantly impaired this response with moderate
to severe hypoxia (Fig. 8B). Combined application of
iberiotoxin with either L-NAME or 6(Z),15(Z)-20-HEDE had
minimal additional effect on the response of vessels to incremental
hypoxia beyond that determined in iberiotoxin-treated vessels alone. In contrast, treatment of vessels with both iberiotoxin and indomethacin completely eliminated the dilation of the vessels in response to
reduced PO2.
|
| |
DISCUSSION |
|---|
|
|
|---|
Given that investigations of mechanisms for vascular reactivity to hypoxia have demonstrated considerable heterogeneity regarding the signaling pathways involved, the purpose of the present study was to begin to assemble the predominant mediators of hypoxic dilation of skeletal muscle microvessels into a more integrated framework. Previous studies suggested that release of endothelium-derived NO (14, 22), prostacyclin (5-8, 15, 17, 19, 20), or EETs (6) mediates the dilation of rat skeletal muscle microvessels in response to large, discrete reductions in PO2, with additional evidence suggesting that a reduction in vascular levels of 20-HETE (6, 7, 11, 16) could also play a role in mediating this response. However, many of these studies suggest that a specific mediator dominates this response, with little contribution from other signaling pathways toward determining the net reactivity of skeletal muscle microvessels to reduced oxygen tension. The results of the present study suggest that the net response of skeletal muscle resistance arteries of Sprague-Dawley rats to incremental reductions in PO2 represents an integration of NO-dependent, PGI2-dependent, and 20-HETE-dependent signaling pathways, mediated via the opening of KATP and KCa channels, with minimal evidence supporting a role for EETs in this process. In addition, the dilation of skeletal muscle resistance arteries in response to incremental hypoxia also appears to reflect primarily alterations in VSM transmembrane potential (Fig. 1C) and may not have been due to other processes [e.g., the production of substances affecting the sensitivity of the muscle contractile filaments (23)]. Furthermore, the present results clearly suggest that reactivity of these vessels to reduced oxygen tension is not wholly endothelium dependent, as ~20% of the normal vessel responses to hypoxia were retained after removal of the vascular endothelium (Fig. 2, A and B). Most interestingly, the present results suggest that each of these signaling pathways exerts its effect over a somewhat distinct range of reduced PO2 and that the relative contribution of each pathway to determining the net response of the arteries to reduced PO2 changes with the severity of hypoxia.
With mild hypoxia (15% O2), the mechanical, electrophysiological, and biochemical data obtained in the present study suggest that arterial dilation and VSM cell membrane hyperpolarization depend on the release of NO from the vascular endothelium, with minimal apparent contribution from either reduced vascular levels of 20-HETE or increased production of endothelium-derived PGI2. Additional experiments suggested that this response depends primarily on the opening of KCa channels, as vessel dilation and VSM hyperpolarization in response to mild hypoxia were unaltered after treatment of vessels with glibenclamide, but were abolished after application of iberiotoxin. With moderate reductions in PO2 (10% O2), it appears that the increased arterial dilation and the greater hyperpolarization of the VSM membrane depend less on additional NO release and are more a function of PGI2 release from the endothelium. The present results also suggest that reduced levels of 20-HETE in the vessels play a role in mediating responses of the arteries to moderate hypoxia. Data collected using the K+ channel antagonists suggest that the response of vessels to moderate hypoxia is mediated through an opening of KATP channels and an additional opening of KCa channels, because both glibenclamide and iberiotoxin attenuated vascular responses to moderate hypoxia. Finally, at the most severe levels of hypoxia (5% O2 and 0% O2), arterial dilation and VSM hyperpolarization appeared to depend primarily on PGI2 release from the endothelium, with minimal further contribution from either NO- or 20-HETE-dependent signaling pathways. The present results also suggest that the responses of vessels to the larger reductions in PO2 are mediated primarily by the opening of KATP channels and are only partially dependent on the opening of KCa channels, because application of glibenclamide severely impaired these responses, whereas application of iberiotoxin resulted in a more modest attenuation.
The additional issue addressed by the present experiments pertains to which K+ channels are affected by the primary mediators of hypoxic dilation and over what range of reduced PO2. On the basis of data presented in Fig. 8, the present results suggest that NO released during mild hypoxia activates KCa channels, causing VSM membrane hyperpolarization and vascular relaxation. This hypothesis is supported by observations that application of L-NAME had no effect on vessels treated with iberiotoxin, but abolished vascular responses to mild hypoxia in arteries treated with glibenclamide. It is also likely that the reduction in vascular 20-HETE levels during moderate hypoxia also causes the opening of KCa channels, leading to VSM hyperpolarization and vascular relaxation. The latter conclusion is supported by a previous study demonstrating that 20-HETE inhibits the opening of KCa channels in renal microvessels and that decreasing 20-HETE concentration removes this inhibition (25). As with NO, this appears to be a reasonable hypothesis, given that treatment of vessels with 6(Z),15(Z)-20-HEDE impaired vasodilator responses to reduced PO2 in vessels treated with glibenclamide, but had no effect on vessels treated with iberiotoxin, where the channels that are presumably inhibited by 20-HETE were already blocked. Furthermore, in agreement with previous studies (5, 17), the PGI2 produced during moderate to severe hypoxia appears to exert its effects via KATP channels, because application of indomethacin to vessels treated with glibenclamide had no additional effect on vessel responses to incremental hypoxia, but application of the COX inhibitor indomethacin to arteries treated with iberiotoxin abolished the dilation of gracilis arteries in response to reduced PO2. Finally, the biochemical data describing the production of these three mediators of hypoxic dilation provide additional support for these hypotheses, in that the PO2 range over which the production of the individual metabolites occurs appears to be highly correlated with mechanical and electrophysiological responses of these vessels to incremental hypoxia. It is important to note that experiments aimed at determining mechanical and electrophysiological responses of isolated vessels in response to graded hypoxia employed cannulated, pressurized resistance arteries, whereas experiments determining metabolite production with incremental hypoxia used pooled (i.e., nonpressurized) vessels. Although these experimental conditions are not directly comparable and the effects of intraluminal pressure on metabolite production in this model are not well defined, to our knowledge, these represent the first systematic studies of the production and/or release of these metabolites with progressive reductions in PO2.
One intriguing observation of the present study was that pharmacological inhibition of the vasoconstrictor metabolite 20-HETE did not alter resting arterial tone. Although puzzling, our observation is consistent with results of previous studies of in situ skeletal muscle arterioles (11, 16), in vitro skeletal muscle arterioles (7, 14), and in vitro renal arteries and arterioles (2). Furthermore, vessel dilation after CP450 4A enzyme inhibition has only been identified after endothelium removal in isolated renal (2) and skeletal muscle arteries (7). Hypotheses of possible mechanisms explaining how alleviation of a constrictor influence (20-HETE) causes dilation of endothelium-denuded vessels only recently have been forwarded (2). In that study, the authors hypothesized that CP450 4A enzyme inhibitors may not alter diameter of intact arterioles as they block formation of both a vasoconstrictor in VSM cells and a vasodilator in the endothelium, thus generating a measurable effect in endothelium-denuded vessels only. A second hypothesis forwarded in that study suggested that basal NO release from the endothelium inhibits the formation of 20-HETE in VSM cells, limiting 20-HETE concentration. Endothelium removal eliminates this effect and allows 20-HETE levels to rise in VSM, thus CP450 enzyme inhibitors would block a higher level of 20-HETE production in endothelium-denuded vessels, causing the observed dilator response (2). These hypotheses warrant future investigation.
The results of the present study may provide insight into the existing divergence of opinion regarding the mediators of hypoxic dilation in skeletal muscle microvessels. Previous studies from our laboratory and others have indicated that the reactivity of skeletal muscle microvessels in response to alterations in PO2 may depend on NO release (14, 22), PGI2 release (5, 7, 15, 17, 19, 20), or EET release (6) from the endothelium and could also depend, in part, on a reduction in 20-HETE levels within VSM cells (7, 11, 16). Possible explanations for the disparity in these results may reflect issues of differences in the specific tissue used [gracilis muscle (5-8) vs. spinotrapezius muscle (22) or cremaster muscle (11, 16, 19, 20)]; longitudinal position within microvascular networks [resistance arteries (5-8) vs. large arterioles (14, 19, 20) vs. distal arterioles (11, 16, 22)]; the use of in situ preparations (11, 16, 22) vs. in vitro preparations (5-8, 14, 17, 19, 20); or animal species and strain differences [Sprague-Dawley (7, 8, 11, 15, 19, 20, 22) vs. Dahl rats (6) or rats vs. hamsters (16)].
In conclusion, when integrated, the data from the present
study, which combine measurements of microvessel diameter, VSM
transmembrane potential, and biochemical analyses under a series of
physiologically and pharmacologically imposed conditions, may begin to
provide a more informative framework for understanding the response of skeletal muscle resistance arteries to hypoxia than has been available previously. With mild hypoxia (15% O2), the small dilation
and VSM hyperpolarization that occur in these vessels appear to be primarily due to the release of NO from the vascular endothelium, acting to open VSM KCa channels. As the severity of hypoxia
increases (10% O2), the rate of NO release from the
endothelium plateaus and vascular production of 20-HETE declines,
causing additional opening of KCa channels from levels
occurring during mild hypoxia. The release of PGI2 from the
vascular endothelium is also increased under these conditions,
activating KATP channels and contributing to the developing
dilation of the vessel and increased hyperpolarization of the VSM cell
membrane. Finally, with severe hypoxia (5% O2 and 0%
O2), endothelial production of PGI2 increases
sharply, further opening KATP channels, acting (with
relatively stable levels of NO and 20-HETE) to cause the large dilation
and VSM hyperpolarization that occur in the vessels during severe
reductions in PO2. These data are summarized
graphically in Fig. 9. These observations
demonstrate the importance of incorporating the entire physiological
range of stimulus magnitude in future studies of vascular responses to
stimuli such as altered oxygen availability. Continuing application of
large and discrete alterations in stimulus magnitude to physiological
systems that respond to inherently continuous variables could fail to
elucidate much of the intricate nature and subtlety of the systems
under investigation.
|
| |
ACKNOWLEDGEMENTS |
|---|
The authors thank L. Kelley, L. Henderson, and L. de la Cruz for expert technical assistance regarding the biochemical assays used for this study.
| |
FOOTNOTES |
|---|
This study was supported by National Institutes of Health Grants HL-65289, HL-29587, HL-37374, and GM-31278 and grants from the Medical College of Wisconsin (to J. C. Frisbee) and the Robert A. Welch Foundation (J. R. Falck).
Address for reprint requests and other correspondence: J. C. Frisbee, Dept. of Physiology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226 (E-mail: jfrisbee{at}mcw.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
March 29, 2002;10.1152/ajpregu.00741.2001
Received 17 December 2001; accepted in final form 25 March 2002.
| |
REFERENCES |
|---|
|
|
|---|
1.
Alonso-Galicia, M,
Falck JR,
Reddy KK,
and
Roman RJ.
20-HETE agonists and antagonists in the renal circulation.
Am J Physiol Renal Physiol
277:
F790-F796,
1999
2.
Alonso-Galicia, M,
Sun CW,
Falck JR,
Harder DR,
and
Roman RJ.
Contribution of 20-HETE to the vasodilator actions of nitric oxide in renal arteries.
Am J Physiol Renal Physiol
275:
F370-F378,
1998
3.
Bonnet, P,
Gebremedhin D,
Rusch NJ,
and
Harder DR.
Effects of hypoxia on a potassium channel in cat cerebral arterial muscle cells.
Z Kardiol
80, Suppl7:
25-27,
1991[ISI][Medline].
4.
Christensen, KL,
and
Mulvany MJ.
Location of resistance arteries.
J Vasc Res
38:
1-12,
2001[ISI][Medline].
5.
Fredricks, KT,
Liu Y,
and
Lombard JH.
Response of extraparenchymal resistance arteries of rat skeletal muscle to reduced PO2.
Am J Physiol Heart Circ Physiol
267:
H706-H715,
1994
6.
Frisbee, JC,
Roman RJ,
Krishna UM,
Falck JR,
and
Lombard JH.
Altered mechanisms of hypoxic dilation in skeletal muscle arteries between normotensive and hypertensive Dahl salt-sensitive rats.
Microcirculation
8:
115-127,
2001[ISI][Medline].
7.
Frisbee, JC,
Roman RJ,
Krishna UM,
Falck JR,
and
Lombard JH.
Relative contribution of cyclooxygenase and cytochrome P450
-hydroxylase-dependent pathways to hypoxic dilation of skeletal muscle resistance arteries.
J Vasc Res
38:
305-314,
2001[ISI][Medline].
8.
Frisbee, JC,
Sylvester FA,
and
Lombard JH.
High salt diet impairs hypoxia- and prostacyclin-induced cellular signaling in skeletal muscle resistance arteries.
Am J Physiol Heart Circ Physiol
281:
H1808-H1815,
2001
9.
Gebremedhin, D,
Bonnet P,
Greene AS,
England SK,
Rusch NJ,
Lombard JH,
and
Harder DR.
Hypoxia increases the activity of Ca2+-sensitive K+ channels in cat cerebral arterial muscle cell membranes.
Pflügers Arch
428:
621-630,
1994[ISI][Medline].
10.
Granger, HJ.
Local regulation of blood flow by resistance vessels sensitive to shear rate, stretch and tissue metabolites.
In: Biology of the Ocular Microcirculation, edited by Weinreb RN,
Joyner WL,
and Wheeler LA.. New York: Elsevier Science, 1992, p. 13-25.
11.
Harder, DR,
Narayanan J,
Birks EK,
Liard JF,
Imig JD,
Lombard JH,
Lange AR,
and
Roman RJ.
Identification of a putative microvascular oxygen sensor.
Circ Res
79:
54-61,
1996
12.
Imig, JD,
Falck JR,
and
Inscho EW.
Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to afferent arteriolar autoregulatory responsiveness.
Br J Pharmacol
127:
1399-1405,
1999[ISI][Medline].
13.
Johnson, PC,
and
Smiesko V.
Overview of regulatory mechanisms in the microcirculation.
In: Flow-Dependent Regulation of Vascular Function, edited by Bevan JA,
Kaley G,
and Rubanyi GM.. Oxford: Oxford University Press, 1995, p. 261-273.
14.
Kerkhof, CJM,
Bakker ENTP,
and
Sipkema P.
Role of cytochrome P-450 4A in oxygen sensing and NO production in rat cremaster resistance arteries.
Am J Physiol Heart Circ Physiol
277:
H1546-H1552,
1999
15.
Liu, Y,
Fredricks KT,
Roman RJ,
and
Lombard JH.
Response of resistance arteries to reduced PO2 and vasodilators during hypertension and elevated salt intake.
Am J Physiol Heart Circ Physiol
273:
H869-H877,
1997
16.
Lombard, JH,
Kunert MP,
Roman RJ,
Falck JR,
Harder DR,
and
Jackson WF.
Cytochrome P450
-hydroxylase senses O2 in hamster muscle, but not cheek pouch epithelium, microcirculation.
Am J Physiol Heart Circ Physiol
276:
H503-H508,
1999
17.
Lombard, JH,
Liu Y,
Fredricks KT,
Bizub DM,
Roman RJ,
and
Rusch NJ.
Electrical and mechanical responses of rat middle cerebral arteries to reduced PO2 and prostacyclin.
Am J Physiol Heart Circ Physiol
276:
H509-H516,
1999
18.
Maier, KG,
Henderson L,
Narayanan J,
Alonso-Galicia M,
Falck JR,
and
Roman RJ.
Fluorescent HPLC assay for 20-HETE and other P-450 metabolites of arachidonic acid.
Am J Physiol Heart Circ Physiol
279:
H863-H871,
2000
19.
Messina, EJ,
Sun D,
Koller A,
Wolin MS,
and
Kaley G.
Increases in oxygen tension evoke arteriolar constriction by inhibiting endothelial prostaglandin synthesis.
Microvasc Res
48:
151-160,
1994[ISI][Medline].
20.
Messina, EJ,
Sun D,
Koller A,
Wolin MS,
and
Kaley G.
Role of endothelium-derived prostaglandins in hypoxia elicited arteriolar dilation in rat skeletal muscle.
Circ Res
71:
790-796,
1992
21.
Miura, H,
Yiu Y,
and
Gutterman DD.
Human coronary arteriolar dilation to bradykinin depends on membrane hyperpolarization: contribution of nitric oxide and Ca2+-activated K+ channels.
Circulation
99:
3132-3138,
1999
22.
Pries, AR,
Heide J,
Ley K,
Klotz KF,
and
Gaehtgens P.
Effect of oxygen tension on regulation of arteriolar diameter in skeletal muscle in situ.
Microvasc Res
49:
289-299,
1995[ISI][Medline].
23.
Ungvari, Z,
and
Koller A.
NO released to flow reduces myogenic tone of skeletal muscle arterioles by decreasing smooth muscle Ca2+ sensitivity.
J Appl Physiol
91:
522-527,
2001
24.
Wang, MH,
Brand-Schieber E,
Zand BA,
Nguyen X,
Falck JR,
Balu N,
and
Schwartzman ML.
Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors.
J Pharmacol Exp Ther
284:
966-973,
1998
25.
Zou, AP,
Fleming JT,
Falck JR,
Jacobs ER,
Gebremedhin D,
Harder DR,
and
Roman RJ.
20-HETE is an endogenous inhibitor of the large-conductance Ca2+-activated K+ channel in renal arterioles.
Am J Physiol Regulatory Integrative Comp Physiol
270:
R228-R237,
1996
This article has been cited by other articles:
![]() |
P. A. Stapleton, Adam. G. Goodwill, M. E. James, and J. C. Frisbee Altered mechanisms of endothelium-dependent dilation in skeletal muscle arterioles with genetic hypercholesterolemia Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2007; 293(3): R1110 - R1119. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Zhao, A. Adebiyi, Q. Xi, and J. H. Jaggar Hypoxia reduces KCa channel activity by inducing Ca2+ spark uncoupling in cerebral artery smooth muscle cells Am J Physiol Cell Physiol, June 1, 2007; 292(6): C2122 - C2128. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Toth, M. Pal, M. Intaglietta, and P. C. Johnson Contribution of anaerobic metabolism to reactive hyperemia in skeletal muscle Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2643 - H2653. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Quayle, M. R. Turner, H. E. Burrell, and T. Kamishima Effects of hypoxia, anoxia, and metabolic inhibitors on KATP channels in rat femoral artery myocytes Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H71 - H80. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J Ray and J. M Marshall Measurement of nitric oxide release evoked by systemic hypoxia and adenosine from rat skeletal muscle in vivo J. Physiol., November 1, 2005; 568(3): 967 - 978. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Foster, D. C. McKenzie, W. K. Milsom, and A. W. Sheel Effects of two protocols of intermittent hypoxia on human ventilatory, cardiovascular and cerebral responses to hypoxia J. Physiol., September 1, 2005; 567(2): 689 - 699. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Frisbee Reduced nitric oxide bioavailability contributes to skeletal muscle microvessel rarefaction in the metabolic syndrome Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2005; 289(2): R307 - R316. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. S. Win and J. M. Marshall Contribution of prostaglandins to the dilation that follows isometric forearm contraction in human subjects: effects of aspirin and hyperoxia J Appl Physiol, July 1, 2005; 99(1): 45 - 52. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Drenjancevic-Peric, S. A. Phillips, J. R. Falck, and J. H. Lombard Restoration of normal vascular relaxation mechanisms in cerebral arteries by chromosomal substitution in consomic SS.13BN rats Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H188 - H195. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wang, R. J. Roman, J. R. Falck, L. de la Cruz, and J. H. Lombard Effects of high-salt diet on CYP450-4A {omega}-hydroxylase expression and active tone in mesenteric resistance arteries Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1557 - H1565. [Abstract] [Full Text] [PDF] |
||||